ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.

Vincent Planche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.